Business
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal’s extensive domestic pharmaceutical manufacturing footprint BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), an American biopharmaceutical company, and Apiject Systems, Corp. (“Apiject”), a medical technology company focused on advanced drug delivery, to
About this update from Amneal Pharmaceuticals, Inc.
[{"type":"image","alt":"Amneal Pharmaceuticals LLC","displaySize":"","headline":null,"caption":"Amneal Pharmaceuticals LLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":158,"url":"https://media.zenfs.com/en/globenewswire.com/0dcbe458b6c7d29ff886bdd0adf21ba0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/H9ZxvrHS3ZfedaWwTsUXWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0dcbe458b6c7d29ff886bdd0adf21ba0","width":300,"height":158}},"lazy":false},{"type":"text","content":"-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation","length":153,"tagName":"p"},{"type":"text","content":"-Expands Amneal’s extensive domestic pharmaceutical manufacturing footprint","length":75,"tagName":"p"},{"type":"text","content":"BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), an American biopharmaceutical company, and Apiject Systems, Corp. (“Apiject”), a medical technology company focused on advanced drug delivery, today announced a strategic collaboration to expand domestic production of Apiject’s BFS-based injectable platform at Amneal’s Brookhaven, NY facility. The collaboration will enable large-scale capacity to produce a range of sterile drug dosage forms, including prefilled injectables, ophthalmics and inhalation.","length":580,"tagName":"p"},{"type":"text","content":"Today, Amneal has one of the largest U.S. pharmaceutical manufacturing footprints in the industry. This collaboration underscores Amneal’s commitment to strengthening U.S. drug supply through domestic pharmaceutical manufacturing. Currently, the Company has approximately 2,500 employees in the U.S., with the majority focused on operations, quality, and R&D. At the Brookhaven, NY facility, Amneal has approximately 800 employees and this project is expected to create approximately 200 high-quality jobs.","length":510,"tagName":"p"},{"type":"text","content":"“This collaboration marks a significant step in expanding our U.S. manufacturing footprint with advanced sterile pharmaceutical capabilities,” said Chirag and Chintu Patel, Co-Chief Executive Officers of Amneal Pharmaceuticals. “We continue to invest in advanced pharmaceutical manufac...